Article

The significance of lobular neoplasia on needle core biopsy of the breast.

Department of Histopathology, Nottingham University Hospital, City Hospital Campus, Hucknall Road, Nottingham NG5 1PB, UK.
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin (Impact Factor: 2.56). 06/2008; 452(5):473-9. DOI: 10.1007/s00428-008-0607-8
Source: PubMed

ABSTRACT The management of a core biopsy diagnosis of lobular neoplasia is controversial. Detailed radiological-pathological review of 47 patients with cores showing classical lobular neoplasia was performed (patients with pleomorphic lobular carcinoma in situ (LCIS) or associated risk lesions were considered separately). Immediate surgical excision in 25 patients showed invasive carcinoma in 7, ductal carcinoma in situ (DCIS) in 1 and pleomorphic LCIS in 1; radiological-pathological review showed that the core biopsy missed a mass in 5, missed calcification in 2 and that calcification appeared adequately sampled in 2. Nineteen patients had follow-up of at least 2 years. Four patients developed malignancy at the site of the core biopsy (invasive carcinoma in three, DCIS in one); one carcinoma was mammographically occult, one patient had dense original mammograms and two had calcifications apparently adequately sampled by the core. In conclusion, most carcinomas identified at the site of core biopsy showing lobular neoplasia were the result of the core missing the radiological lesion, emphasising the importance of multidisciplinary review and investigation of any discordance. Some carcinomas were found after apparently adequate core biopsy, raising the question of whether excision biopsy should be considered after all core biopsy diagnoses of lobular neoplasia.

0 Bookmarks
 · 
110 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: AIMS: The management of lobular in situ neoplasia (LN) when diagnosed on core biopsy remains a controversial issue. The present study aimed to investigate the association between morphological parameters of LN on vacuum-assisted needle core biopsy (VANCB) and the presence of malignancy (ductal carcinoma in situ, pleomorphic lobular carcinoma in situ, or invasive carcinoma) at surgical excision (SE). METHODS AND RESULTS: The study included 14 pathology departments in Italy. Available slides from 859 cases of VANCB reporting an original diagnosis of flat epithelial atypia, atypical ductal hyperplasia or LN, all with subsequent surgical excision, were reviewed. Overall, 286 cases of LN, pure or associated with other lesions, were identified, and a malignant outcome was reported at excision for 51 cases (17.8%). Among the 149 cases of pure LN, an increased risk of malignancy emerged in women in mammographic categories R4-R5 as compared with those in categories R2-R3 (OR 2.46; P = 0.048). In the series, a statistically significant decreased malignancy risk emerged among cases without determinant microcalcifications (P = 0.04). CONCLUSIONS: Our results suggest that the diagnosis of pure LN on VANCB warrants follow-up excision, because clinicopathological parameters do not allow the prediction of which cases will present carcinoma at surgical excision.
    Histopathology 03/2013; · 3.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Breast carcinoma in situ (CIS) is classified into ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS). DCIS is treated with surgical excision while LCIS can be clinically followed with or without hormonal treatment. Thus, it is critical to distinguish DCIS from LCIS. Immunohistochemical (IHC) staining for E-cadherin is routinely used to differentiate DCIS from LCIS in diagnostically challenging cases. Circumferential diffuse membranous staining of E-cadherin is the typical pattern in DCIS, whereas LCIS lacks or shows decreased E-cadherin expression. Recent studies have shown that DCIS has membranous staining of P120 catenin and LCIS has diffuse cytoplasmic staining of P120 catenin. We developed a cocktail composed of E-cadherin and P120 catenin primary antibodies so that only one slide is needed for the double immunostains.
    International journal of clinical and experimental pathology. 01/2014; 7(5):2551-7.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Kolumnarzellläsionen (CCL) und lobuläre Neoplasien (LN) werden in Mammographie-Screening-Biopsien immer häufiger diagnostiziert. Der mammographische Leitbefund der CCL ist Mikrokalk (MK), LN sind meist Zufallsbefunde. Beide Läsionen – und speziell die flache Epithelatypie (FEA) als atypische Variante der CCL – sind häufig miteinander und auch mit einer atypischen duktalen Hyperplasie (ADH) assoziiert. Molekularpathologische Befunde von CCL zeigen chromosomale Veränderungen, die auch im duktalen Carcinoma in situ (DCIS) und in invasiven gut differenzierten Karzinomen gefunden werden. Dies unterstützt die Hypothese, dass CCL neoplastische Proliferationen sind. Klinische Befunde deuten darauf hin, dass CCL Indikatorläsionen und nichtobligate Präkanzerosen sind. Es gibt derzeit keine international einheitliche Klassifikation der CCL. Kennzeichnendes Merkmal der LN sind Mutationen im CDH1-(E-Cadherin-)Gen. Alternative genetische Veränderungen im CDH1-Pathway können in immunhistochemisch CDH1-positiven LN zu einem Funktionsverlust von CDH1 führen. Wir stellen die Hypothese auf, dass ein Teil der morphologischen und immunhistochemischen Hybridläsionen (WHO 2003) den LN mit alternativen CDH1-Funktionsverlusten entsprechen könnten. Neuere Verlaufsdaten weisen auf eine höhere Rate ipsilateraler Karzinome bei Patienten mit vorbekannter LN hin. Es ist eine offene Frage, ob die FEA und die LN eine gemeinsame Familie intralobulärer Neoplasien sind, die gemeinsame nichtobligate Vorläufer einer ,,low nuclear grade breast neoplasia family“ sind.
    Der Pathologe 01/2008; 29. · 0.64 Impact Factor

Full-text (2 Sources)

Download
41 Downloads
Available from
Jun 3, 2014